Bone loss (therapy-induced) in non-metastatic prostate cancer - denosumab (terminated appraisal) (TA194) (replaced by CG175)
Denosumab for the treatment of therapy-induced bone loss in non-metastatic prostate cancer
This guidance has been replaced by CG175 Prostate cancer
This page was last updated: 05 March 2014
Implementation tools and resources
- None available
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.